Baxter and biomÉrieux announce ce mark for nephroclear™ ccl14 test to predict persistent severe acute kidney injury

Deerfield, ill. & marcy l'etoile, france--(business wire)--baxter international inc. (nyse:bax), a global leader in acute care, and biomÉrieux (epa:bim), a global leader in in vitro diagnostics, today announced the ce marking of the nephroclear™ ccl14 test. the nephroclear™ ccl14 test is designed to predict persistent severe acute kidney injury (ps-aki) and can be used to support timely clinical decision-making and care pathways. the companies intend to commercially launch the nephroclear™ ccl1
BAX Ratings Summary
BAX Quant Ranking